Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274

Yitzhak Zimmer, Angelina V. Vaseva, Michaela Medová, Bruno Streit, Wieslawa Blank-Liss, Richard H. Greiner, Nikolaus Schiering, Daniel M. Aebersold

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Point mutations emerge as one of the rate-limiting steps in tumor response to small molecule inhibitors of protein kinases. Here we characterized the response of the MET mutated variants, V1110I, V1238I, V1206L and H1112L to the small molecule SU11274. Our results reveal a distinct inhibition pattern of the four mutations with IC50 values for autophosphorylation inhibition ranging between 0.15 and 1.5 μM. Differences were further seen on the ability of SU11274 to inhibit phosphorylation of downstream MET transducers such as AKT, ERK, PLCγ and STAT3 and a variety of MET-dependent biological endpoints. In all the assays, H1112L was the most sensitive to SU11274, while V1206L was less affected under the used concentration range. The differences in responses to SU11274 are discussed based on a structural model of the MET kinase domain.

Original languageEnglish (US)
Pages (from-to)228-236
Number of pages9
JournalCancer Letters
Issue number2
StatePublished - Mar 28 2010
Externally publishedYes


  • Drug resistance
  • MET
  • Point mutations
  • Receptor tyrosine kinases
  • SU11274

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274'. Together they form a unique fingerprint.

Cite this